RxDoctor Payments Data

Manuel Marquez

Family · Fairfield, CTNPI 1740532977

Payments from drug & device makers

$7,464in general payments, 2019–2025

Across 235 payments — averaging $31.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Scilex Pharmaceuticals Inc.$1K
  • Collegium Pharmaceutical, Inc.$780
  • AbbVie$767
  • Nevro Corp.$345
  • Idorsia Pharmaceuticals US Inc$231
  • plus $1K from 19 others

What the payments were for

  • Travel & lodging$1,89325%
  • Food & beverage$5,57175%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,464 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$128,563
Medicare patients
266
Services billed
1,281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PercocetOxycodone Hcl/Acetaminophen33$118,247
ZtlidoLidocaine203$96,977
Xtampza ErOxycodone Myristate66$46,121
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,403$36,329
OxycontinOxycodone Hcl43$34,113
BelbucaBuprenorphine Hcl36$30,534
Oxycodone Hcl903$17,649
MovantikNaloxegol Oxalate40$16,452
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen485$13,028
Lidocaine94$11,258
Diclofenac Sodium159$9,864
Pregabalin355$9,063
Buprenorphine24$7,979
Fentanyl97$7,424
SymproicNaldemedine Tosylate15$7,419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Scilex Pharmaceuticals Inc.Ztlido$1,108$96,977203 claims
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$780$76,655102 claims
Redhill Biopharma Inc.Movantik$18$16,45240 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$65$10,655131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.

Other family in Fairfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →